These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 21572302)

  • 1. Antibody and B-cell responses may control circulating lipopolysaccharide in patients with HIV infection.
    Lim A; Amini A; D'Orsogna LJ; Rajasuriar R; Kramski M; Lewin SR; Purcell DF; Price P; French MA
    AIDS; 2011 Jul; 25(11):1379-83. PubMed ID: 21572302
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Distinct mechanisms for mitochondrial DNA loss in T and B lymphocytes from HIV-infected patients exposed to nucleoside reverse-transcriptase inhibitors and those naive to antiretroviral treatment.
    Maagaard A; Holberg-Petersen M; Løvgården G; Holm M; Pettersen FO; Kvale D
    J Infect Dis; 2008 Nov; 198(10):1474-81. PubMed ID: 18851688
    [TBL] [Abstract][Full Text] [Related]  

  • 3. B cell immunopathology during HIV-1 infection: lessons to learn for HIV-1 vaccine design.
    Cagigi A; Nilsson A; De Milito A; Chiodi F
    Vaccine; 2008 Jun; 26(24):3016-25. PubMed ID: 18164520
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HIV-1 Tat dysregulation of lipopolysaccharide-induced cytokine responses: microbial interactions in HIV infection.
    Yim HC; Li JC; Lau JS; Lau AS
    AIDS; 2009 Jul; 23(12):1473-84. PubMed ID: 19622906
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Resistance to infection by HIV-1 of peripheral blood mononuclear cells from HIV-1-infected patients is probably mediated by neutralizing antibodies.
    Tremblay M; Numazaki K; Li XG; Gornitsky M; Hiscott J; Wainberg MA
    J Immunol; 1990 Nov; 145(9):2896-901. PubMed ID: 1698866
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low CD4 T-cell counts despite low levels of circulating HIV: insights from the comparison of HIV-1 infected patients with a discordant response to antiretroviral therapy to patients with untreated advanced HIV-2 disease.
    Albuquerque AS; Foxall RB; Cortesão CS; Soares RS; Doroana M; Ribeiro A; Lucas M; Antunes F; Victorino RM; Sousa AE
    Clin Immunol; 2007 Oct; 125(1):67-75. PubMed ID: 17692571
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Loss of HIV-specific memory B-cells as a potential mechanism for the dysfunction of the humoral immune response against HIV.
    Bussmann BM; Reiche S; Bieniek B; Krznaric I; Ackermann F; Jassoy C
    Virology; 2010 Feb; 397(1):7-13. PubMed ID: 19962720
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circulating memory B-cell subpopulations are affected differently by HIV infection and antiretroviral therapy.
    D'Orsogna LJ; Krueger RG; McKinnon EJ; French MA
    AIDS; 2007 Aug; 21(13):1747-52. PubMed ID: 17690573
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular characterization of the circulating anti-HIV-1 gp120-specific B cell repertoire using antibody phage display libraries generated from pre-selected HIV-1 gp120 binding PBLs.
    Koefoed K; Farnaes L; Wang M; Svejgaard A; Burton DR; Ditzel HJ
    J Immunol Methods; 2005 Feb; 297(1-2):187-201. PubMed ID: 15777942
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunophenotypic markers and antiretroviral therapy (IMART): T cell activation and maturation help predict treatment response.
    Mildvan D; Bosch RJ; Kim RS; Spritzler J; Haas DW; Kuritzkes D; Kagan J; Nokta M; DeGruttola V; Moreno M; Landay A
    J Infect Dis; 2004 May; 189(10):1811-20. PubMed ID: 15122517
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Persistent microbial translocation and immune activation in HIV-1-infected South Africans receiving combination antiretroviral therapy.
    Cassol E; Malfeld S; Mahasha P; van der Merwe S; Cassol S; Seebregts C; Alfano M; Poli G; Rossouw T
    J Infect Dis; 2010 Sep; 202(5):723-33. PubMed ID: 20629534
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Restoration of the antibody response upon rabies vaccination in HIV-infected patients treated with HAART.
    Gelinck LB; Jol-van der Zijde CM; Jansen-Hoogendijk AM; Brinkman DM; van Dissel JT; van Tol MJ; Kroon FP
    AIDS; 2009 Nov; 23(18):2451-8. PubMed ID: 19741483
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biological determinants of immune reconstitution in HIV-infected patients receiving antiretroviral therapy: the role of interleukin 7 and interleukin 7 receptor α and microbial translocation.
    Rajasuriar R; Booth D; Solomon A; Chua K; Spelman T; Gouillou M; Schlub TE; Davenport M; Crowe S; Elliott J; Hoy J; Fairley C; Stewart G; Cameron P; Lewin SR
    J Infect Dis; 2010 Oct; 202(8):1254-64. PubMed ID: 20812848
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systemic antibody responses to gut commensal bacteria during chronic HIV-1 infection.
    Haas A; Zimmermann K; Graw F; Slack E; Rusert P; Ledergerber B; Bossart W; Weber R; Thurnheer MC; Battegay M; Hirschel B; Vernazza P; Patuto N; Macpherson AJ; Günthard HF; Oxenius A;
    Gut; 2011 Nov; 60(11):1506-19. PubMed ID: 21515549
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HIV-1 Tat-specific IgG antibodies in high-responders target a B-cell epitope in the cysteine-rich domain and block extracellular Tat efficiently.
    Kashi VP; Jacob RA; Paul S; Nayak K; Satish B; Swaminathan S; Satish KS; Ranga U
    Vaccine; 2009 Nov; 27(48):6739-47. PubMed ID: 19744585
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anticardiolipin antibodies in HIV infection are independently associated with antibodies to the membrane proximal external region of gp41 and with cell-associated HIV DNA and immune activation.
    Martinez V; Diemert MC; Braibant M; Potard V; Charuel JL; Barin F; Costagliola D; Caumes E; Clauvel JP; Autran B; Musset L;
    Clin Infect Dis; 2009 Jan; 48(1):123-32. PubMed ID: 19035778
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of combination antiretroviral therapy on CD5 B- cells, B-cell activation and hypergammaglobulinaemia in HIV-1-infected patients.
    Redgrave BE; Stone SF; French MA; Krueger R; James IR; Price P
    HIV Med; 2005 Sep; 6(5):307-12. PubMed ID: 16156877
    [TBL] [Abstract][Full Text] [Related]  

  • 18. AIDS/HIV. A boost for HIV vaccine design.
    Burton DR; Weiss RA
    Science; 2010 Aug; 329(5993):770-3. PubMed ID: 20705840
    [No Abstract]   [Full Text] [Related]  

  • 19. Microbial translocation correlates with the severity of both HIV-1 and HIV-2 infections.
    Nowroozalizadeh S; Månsson F; da Silva Z; Repits J; Dabo B; Pereira C; Biague A; Albert J; Nielsen J; Aaby P; Fenyö EM; Norrgren H; Holmgren B; Jansson M
    J Infect Dis; 2010 Apr; 201(8):1150-4. PubMed ID: 20199244
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the possible influence of hepatitis C virus and liver fibrosis on HIV type 1 immunological and virological outcomes.
    Collazos J; Cartón JA; Asensi V
    HIV Med; 2011 May; 12(5):308-15. PubMed ID: 20946441
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.